Covid-19 Vaccination

Latest news, daily rates, information and updates

Last updated 02 June, 2023 10:30 CEST

As the coronavirus vaccine rolls out across the globe on this page you will find all our latest Covid-19 vaccine updates and live tracking of vaccine development and administration.

You can explore our data and find insights into Covid-19 vaccine clinical trials, country-level vaccination statistics, the impact of vaccination on infection and death rates, and all the latest news and information on the Covid-19 vaccination.

Number of vaccine doses administered globally

13,390,575,075

+160,172 reported yesterday

Number of fully vaccinated globally

5,128,594,674

+78,524 reported yesterday

Number of countries with a vaccination programme

217

+2 reported yesterday

Fully vaccinated global population

64.31%

+0% reported yesterday

Coronavirus vaccine roll out statistics by country

Public health authorities across the globe have been mobilising to deliver the biggest ever vaccination programme to battle Covid-19. How many people have received the Covid-19 vaccine? We bring you the latest Covid-19 vaccine numbers, including daily Covid-19 vaccine rates per country. Track worldwide Covid-19 vaccine rates with Pharmaceutical Technology and GlobalData.

Some countries have made a fast start with their vaccination efforts. By the end of January, Israel had successfully vaccinated 3 million people with the first dose. While the US may have had a slow start, President Biden has put the vaccination programme at the forefront of his first 100 days agenda.

Country Doses Administered Doses per 1000 Fully Vaccinated Population (%) Vaccine being used in a country
World 13,390,575,075 1,763.2 6753%
China 3,491,077,000 2,506.6 9167% CanSino, IMBCAMS, KCONVAC, Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac, ZF2001
India 2,206,684,650 1,631.4 7038% Corbevax, Covaxin, Novavax, Oxford/AstraZeneca, Sputnik V
United States 676,728,782 2,068.4 7050% Johnson&Johnson, Moderna, Novavax, Pfizer/BioNTech
Brazil 486,436,436 2,322.2 8410% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Indonesia 444,303,130 1,659.9 6452% Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Japan 383,747,738 3,032.9 8170% Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Bangladesh 358,557,566 2,222.2 8696% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Pakistan 338,642,674 1,595.8 6617% CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Vietnam 266,266,588 2,787.0 8993% Abdala, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Mexico 225,063,079 1,783.5 6550% CanSino, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Germany 192,043,023 2,315.8 7664% Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Valneva
Russia 186,692,479 1,279.3 5462% EpiVacCorona, Sputnik V
Philippines 170,014,442 1,594.1 6935% Covaxin, Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Iran 155,194,752 1,847.7 6972% CanSino, Covaxin, COVIran Barekat, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Soberana02, Sputnik Light, Sputnik V
France 154,451,978 2,305.7 7940% Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sanofi/GSK
Turkey 152,543,341 1,853.1 6460% Pfizer/BioNTech, Sinovac, Turkovac
United Kingdom 151,248,820 2,274.8 7632% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Italy 144,573,878 2,392.4 7937% Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sanofi/GSK
Thailand 142,635,014 2,054.4 7704% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
South Korea 129,647,782 2,510.8 8593% Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Argentina 115,678,735 2,599.8 7839% CanSino, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Egypt 112,284,725 1,097.2 4125% CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Nigeria 108,052,995 551.6 3266% Oxford/AstraZeneca
Spain 105,799,888 2,264.4 8719% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Canada 96,956,502 2,616.3 8571% Johnson&Johnson, Medicago, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Colombia 90,210,929 1,817.0 7442% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Peru 89,452,255 2,796.3 8957% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Uzbekistan 73,580,492 2,232.7 5422% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik Light, Sputnik V, ZF2001
Malaysia 72,629,123 2,253.6 8549% CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Saudi Arabia 68,534,631 2,033.7 7547% Oxford/AstraZeneca, Pfizer/BioNTech
Taiwan 67,913,330 2,876.4 8798% Medigen, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Myanmar 64,549,994 1,201.9 5129% Oxford/AstraZeneca, Sinopharm/Beijing
Australia 63,681,652 2,548.0 8664% Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Chile 62,688,847 3,347.1 9451% CanSino, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Nepal 61,825,430 2,201.1 8672% Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Poland 57,998,335 1,527.1 5963% Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Morocco 55,388,882 1,537.3 6529% CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Ethiopia 54,041,862 494.8 3446% Covaxin, Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac
Cambodia 46,920,796 2,887.5 9020% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Cuba 44,415,297 3,917.3 8833% Abdala, Soberana Plus, Soberana02
Sri Lanka 40,116,590 1,851.3 6808% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Ecuador 39,448,015 2,309.0 8328% CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
South Africa 38,813,021 671.7 3641% Johnson&Johnson, Pfizer/BioNTech
Venezuela 37,860,994 1,311.4 5184% Abdala, Sinopharm/Beijing, Sinovac, Soberana02, Sputnik Light, Sputnik V
Netherlands 36,104,942 2,095.3 6940% Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Tanzania 35,994,687 639.1 5197% Johnson&Johnson, Pfizer/BioNTech, Sinopharm/Beijing
Ukraine 31,668,577 709.7 3396% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Belgium 29,632,916 2,594.4 8027% Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Mozambique 29,457,535 998.7 6701% Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Portugal 28,167,414 2,739.6 8655% Covaxin, Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sanofi/GSK, Sinopharm/Beijing, Sinovac
Uganda 26,299,538 615.6 3034% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Sweden 26,117,645 2,564.8 7498% Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Rwanda 26,106,436 2,122.1 8046% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Angola 25,402,678 824.5 2863% Oxford/AstraZeneca
United Arab Emirates 24,922,054 2,530.0 9941% CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Cote d'Ivoire 24,277,616 968.4 4773% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Kenya 23,132,128 450.1 2114% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Ghana 22,384,226 752.0 3294% Oxford/AstraZeneca, Sputnik V
Greece 22,124,004 2,062.3 7127% Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Kazakhstan 20,918,681 1,144.6 5807% QazVac, Sinopharm/Beijing, Sputnik V
Hong Kong 20,804,837 2,752.0 8995% Pfizer/BioNTech, Sinovac
Austria 20,458,439 2,312.5 7554% Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sanofi/GSK, Valneva
Guatemala 20,346,236 1,179.6 4130% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V
Iraq 19,557,364 508.9 2067% CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Belarus 18,871,846 1,989.6 6758% KoviVac/Chumakov, Sinopharm/Beijing, Sputnik Light, Sputnik V
Tajikistan 18,871,161 2,073.6 5681% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Israel 18,649,248 2,099.2 6934% Moderna, Pfizer/BioNTech
Czechia 18,625,283 1,752.9 6487% Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Honduras 16,987,951 1,771.9 6033% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V
Afghanistan 16,960,754 456.3 3796% CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Switzerland 16,939,200 1,989.0 7061% Johnson&Johnson, Moderna, Novavax, Pfizer/BioNTech
Romania 16,827,486 864.1 4167% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Hungary 16,701,238 1,709.7 6354% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Democratic Republic of Congo 16,398,195 195.1 1531% Oxford/AstraZeneca
Dominican Republic 16,300,581 1,533.9 5735% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Nicaragua 15,328,476 2,370.8 9421% Abdala, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Soberana02, Sputnik Light, Sputnik V
Algeria 15,267,442 361.5 1535% Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V
Denmark 15,061,754 2,598.0 8178% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Singapore 14,727,569 2,611.9 9082% Moderna, Novavax, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Bolivia 14,690,530 1,294.0 5426% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Azerbaijan 13,857,111 1,393.7 4891% Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Sudan 13,711,970 328.0 1986% CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Zambia 13,454,213 775.4 5310% Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Tunisia 13,249,161 1,145.6 5533% CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Finland 13,214,538 2,394.8 7880% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Costa Rica 13,148,135 2,629.9 8696% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Zimbabwe 12,222,754 846.5 3291% Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V
Norway 12,145,560 2,285.4 7630% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
New Zealand 11,977,450 2,451.6 8474% Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
El Salvador 11,289,175 1,758.2 6766% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Ireland 11,122,068 2,291.6 8371% Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Laos 11,111,066 1,527.2 7178% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Jordan 10,057,975 1,010.2 4578% CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Paraguay 9,646,975 1,386.8 5096% Covaxin, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Somalia 9,443,849 629.2 4688% CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Uruguay 9,023,082 2,615.9 8415% Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Panama 8,869,423 2,123.5 7598% Oxford/AstraZeneca, Pfizer/BioNTech
Guinea 8,749,048 704.8 2653% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Serbia 8,534,688 1,222.4 4695% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sputnik V
Kuwait 8,260,050 1,996.5 8086% CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Malawi 8,114,454 447.2 2245% Johnson&Johnson, Oxford/AstraZeneca
Qatar 7,609,178 2,735.5 10253% CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Sierra Leone 7,548,308 986.7 5636% Oxford/AstraZeneca, Sinopharm/Beijing
Niger 7,187,711 320.3 2365% Oxford/AstraZeneca, Sinopharm/Beijing
Oman 7,086,050 1,467.2 6313% CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Chad 6,347,672 410.1 3929% Sinopharm/Beijing
Lebanon 5,814,699 849.0 3525% CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Mali 5,793,606 303.7 1854% Oxford/AstraZeneca
Slovakia 5,754,313 1,056.4 4733% Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V
Mongolia 5,492,919 1,732.7 6863% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Croatia 5,361,915 1,311.2 5506% Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Burkina Faso 5,117,982 245.6 1601% Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Syria 5,090,630 290.9 1348% CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Cameroon 4,735,141 187.8 1232% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Bulgaria 4,612,830 656.7 2958% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Lithuania 4,545,995 1,629.7 6741% Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Liberia 4,460,668 925.6 7742% Oxford/AstraZeneca
South Sudan 4,312,900 392.9 3845% Johnson&Johnson, Oxford/AstraZeneca
Benin 4,232,541 368.5 2388% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Mauritania 4,068,530 924.0 3493% Oxford/AstraZeneca, Sinopharm/Beijing
Palestine 3,748,571 734.8 3483% CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Libya 3,739,158 559.9 1851% CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Kyrgyzstan 3,516,738 556.8 2197% Sinopharm/Beijing, Sputnik V
Bahrain 3,476,633 2,215.2 7817% CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Togo 3,398,445 430.8 1970% Oxford/AstraZeneca
Botswana 3,171,667 1,407.0 7380% Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Albania 3,047,340 1,063.1 4442% Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Slovenia 2,996,643 1,449.5 5912% Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Madagascar 2,940,399 112.0 948% Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Senegal 2,936,343 185.2 910% Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Georgia 2,930,677 785.5 3420% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Latvia 2,895,716 1,503.1 6779% Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Central African Republic 2,893,159 620.0 4857% Covaxin, Oxford/AstraZeneca
Mauritius 2,615,058 2,066.7 8600% Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing
Moldova 2,276,473 642.0 3033% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Armenia 2,150,112 728.4 3340% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac, Sputnik Light, Sputnik V
Estonia 2,112,108 1,599.0 6523% Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Bhutan 2,011,426 2,666.3 8983% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Bosnia and Herzegovina 1,924,950 579.1 2545% Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
North Macedonia 1,862,732 894.3 4024% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac, Sputnik V
Kosovo 1,837,446 995.7 4471% Oxford/AstraZeneca, Pfizer/BioNTech
Macao 1,801,982 2,852.9 10166% Pfizer/BioNTech, Sinopharm/Beijing
Cyprus 1,797,542 1,419.1 5100% Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Trinidad and Tobago 1,580,898 1,137.5 5158% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Fiji 1,555,182 1,760.3 7258% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Jamaica 1,525,895 519.9 2585% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Malta 1,380,865 2,855.8 9752% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Luxembourg 1,373,611 2,260.2 7613% Johnson&Johnson, Moderna, Novavax, Oxford/AstraZeneca, Pfizer/BioNTech
Brunei 1,291,978 2,781.6 9616% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Yemen 1,275,368 44.8 277% CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Lesotho 1,259,488 597.4 4392% Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Namibia 990,210 404.5 2201% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Guyana 953,690 1,224.2 4880% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Maldives 951,742 1,845.5 7469% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Northern Cyprus 861,519 2,312.9 8405% Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Cape Verde 859,940 1,546.7 5553% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Eswatini 853,821 751.5 3719% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech
Comoros 835,021 1,003.2 4771% Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing
Congo 833,210 9.9 78% Moderna, Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V
Gambia 815,861 357.8 1567% Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Guinea-Bissau 810,299 432.3 2848% Oxford/AstraZeneca, Sinopharm/Beijing
Iceland 805,469 2,278.1 8207% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Papua New Guinea 737,695 85.7 373% Oxford/AstraZeneca
Montenegro 679,171 1,091.3 4577% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Solomon Islands 625,956 958.8 3896% Oxford/AstraZeneca
Gabon 572,672 270.2 1214% Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Haiti 515,718 46.4 214% Johnson&Johnson, Moderna
Belize 510,717 1,333.2 5780% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Suriname 505,699 878.0 4130% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
French Polynesia 502,952 1,811.3 6727% Johnson&Johnson, Pfizer/BioNTech
Equatorial Guinea 488,738 373.4 1635% Sinopharm/Beijing, Sinovac
New Caledonia 480,702 1,649.8 6343% Pfizer/BioNTech
Samoa 453,083 2,310.1 9073% Oxford/AstraZeneca
Djibouti 392,703 409.5 3668% CanSino, Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Barbados 381,715 1,331.7 5409% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Vanuatu 366,638 1,252.7 5544% Oxford/AstraZeneca
Bahamas 366,083 949.3 4325% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech
Sao Tome and Principe 262,837 1,245.5 5307% Oxford/AstraZeneca
Curacao 256,029 1,601.7 6253% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Jersey 242,600 2,250.5 7550% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Seychelles 219,489 2,268.3 8439% Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V
Tonga 203,208 1,922.6 7319% Oxford/AstraZeneca
Isle of Man 189,994 2,259.8 7981% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Guernsey 178,525 2,847.0 8406% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Aruba 174,746 1,651.0 7964% Pfizer/BioNTech
Andorra 156,242 2,029.0 6946% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Cayman Islands 151,822 2,365.8 9453% Oxford/AstraZeneca, Pfizer/BioNTech
Antigua and Barbuda 136,512 1,417.8 6479% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Gibraltar 132,810 3,938.8 12298% Oxford/AstraZeneca, Pfizer/BioNTech
Bermuda 132,042 2,064.2 7450% Oxford/AstraZeneca, Pfizer/BioNTech
Saint Lucia 122,977 676.1 3022% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Faeroe Islands 103,894 0% Moderna, Pfizer/BioNTech
Grenada 90,507 812.1 3497% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Greenland 79,738 1,423.3 6874% Moderna, Pfizer/BioNTech
Liechtenstein 74,275 1,959.2 6980% Johnson&Johnson, Moderna, Novavax, Pfizer/BioNTech
Turks and Caicos Islands 73,907 1,962.2 8153% Pfizer/BioNTech
Saint Vincent and the Grenadines 73,443 666.4 2870% Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik Light, Sputnik V
San Marino 69,338 2,052.3 6995% Pfizer/BioNTech, Sputnik V
Dominica 67,647 944.5 4280% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Monaco 65,140 1,684.0 6635% Pfizer/BioNTech
Sint Maarten (Dutch part) 65,095 1,601.2 6522% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Saint Kitts and Nevis 64,297 1,208.0 5073% Oxford/AstraZeneca, Pfizer/BioNTech
Turkmenistan 41,993 7.0 16% EpiVacCorona, Oxford/AstraZeneca, QazVac, Sinopharm/Beijing, Sputnik V, ZF2001
Burundi 37,417 3.3 31% Johnson&Johnson, Sinopharm/Beijing
Bonaire Sint Eustatius and Saba 35,845 1,337.3 6244% Moderna, Pfizer/BioNTech
Nauru 32,157 2,531.3 8931% Oxford/AstraZeneca
Tuvalu 25,591 2,171.7 7911% Oxford/AstraZeneca
Anguilla 24,474 1,354.7 5744% Oxford/AstraZeneca, Pfizer/BioNTech
Wallis and Futuna 18,058 1,142.3 4303% Moderna
Saint Helena 7,892 998.6 4468% Oxford/AstraZeneca
Montserrat 4,619 861.9 3642% Oxford/AstraZeneca
Falkland Islands 4,407 1,091.1 4395% Oxford/AstraZeneca
Micronesia (country) 0 0.0 0%
Vatican 0 0.0 0%
Marshall Islands 0 0.0 0%
Timor-Leste 0 0.0 0%
Eritrea 0 0.0 0%

World map of vaccinations – total doses and fully vaccinated

GlobalData brings you a map of total worldwide Covid-19 vaccination rates per country, which lets you track Covid-19 vaccine numbers as they happen each day.

Total doses tracks the number of vaccine doses applied, whether they be the first or second of the two dose treatments or the one dose vaccine. Fully vaccinated captures the combined number of people to have received either both shots of a two-stage vaccine or the one-shot vaccine. See which countries are administering most Covid-19 vaccines and where efforts are falling short.

The first ever dose of Covid-19 vaccine was administered in the UK in December 2020, and the global vaccination effort has fast expanded with most countries beginning to start their vaccination programmes.

However, supply issues which have hit the EU in January and vaccine poverty fears in the developing world still pose challenges for the worldwide Covid-19 vaccine roll-out.

GlobalData brings you a map of total worldwide Covid-19 vaccination rates per country, which lets you track Covid-19 vaccine first dose and second dose numbers as they happen each day. See which countries are administering most Covid-19 vaccines and where efforts are falling short.

With the worldwide first dose vaccination administered in the UK in December 2020, the global Covid-19 vaccination effort has fast expanded with most countries beginning to start their vaccination programmes. However, supply issues which have hit the EU in January and vaccine poverty fears in the developing world still pose challenges for the worldwide Covid-19 vaccine roll-out.

Global Covid-19 vaccinations

This Covid-19 vaccination chart shows a steadily growing Covid-19 vaccination rate globally since January 2021, the first full month of the global Covid-19 vaccination drive. For more details also see GlobalData’s intelligence on Covid-19 vaccinations per country.

Country-level Covid-19 vaccination

With Israel having a head start with Covid-19 vaccine numbers, many countries are stepping up their effort to battle new cases and death rates with fast Covid-19 vaccine roll-outs.

Vaccines administered

Vaccine doses per 1,000 people

Fully vaccinated population

Leading vaccine candidates and current status

At the start of February nine approved Covid-19 vaccines were being used globally to fight the rising global death rate from Covid-19. The Janssen vaccine is likely to achieve imminent approval and there are almost 50 other Covid-19 vaccines still in development. Some might never progress to regulatory approval, but with new variants of Covid-19 spreading fast the race for the most effective and affordable Covid-19 vaccine is still on. Follow GlobalData’s tracker on Covid-19 vaccine initiatives and Covid-19 vaccine trials here:

Progress: Trial Results expected Awaiting approval Available to public
Trial size Doses requierd Storage temperature Efficacy Number of countries approved

Pfizer/BioNTech 46,331 2 8°C to -90°C 95.0% 49

mRNA vaccine, first to demonstrate positive Phase 3 results. Impressive efficacy of 95% in prevention of COVID-19, with a single drawback of requiring unusually cold (-70 degrees F) conditions for storage and transportation in some regions.

Trial Start Date - 29 April 2020
Result Publication Date - 31 May 2022
31 May, 2022: Emergency Use Authorization given by the Macau
23 Dec, 2022: Complete Approval given by Hong Kong
16 Dec, 2022: Provisional Approval given by New Zealand
9 Dec, 2022: Emergency Use Authorization given by China
6 Dec, 2022: Emergency Use Authorization given by Israel
20 Oct, 2022: Emergency Use Authorization given by EU
5 Oct, 2022: Emergency Use Authorization given by Japan
9 Sep, 2022: Emergency Use Authorization given by Singapore
29 Sep, 2022: Emergency Use Authorization given by Australia
16 Sep, 2022: Emergency Use Authorization given by EU
9 Sep, 2022: Emergency Use Authorization given by Canada
30 Aug, 2022: Emergency Use Authorization given by Japan
19 Aug, 2022: Emergency Use Authorization given by Canada
8 Jul, 2022: Emergency Use Authorization given by the US
17 Jun, 2022: Emergency Use Authorization given by the US
17 May, 2022: Emergency Use Authorization given by the US
8 Apr, 2022: Emergency Use Authorization given by Australia
29 Mar, 2022: Emergency Use Authorization given by the US
24 Mar, 2022: Complete Approval given by Japan
24 Feb, 2022: Emergency Use Authorization given by EU
23 Feb, 2022: Emergency Use Authorization given by South Korea
30 Jan, 2022: Complete Approval given by Qatar
28 Jan, 2022: Emergency Use Authorization given by Australia
21 Jan, 2022: Emergency Use Authorization given by Japan
09 Jan, 2022: Complete Approval given by Qatar
06 Jan, 2022: Emergency Use Authorization given by Malaysia
06 Jan, 2022: Complete Approval given by Brazil
04 Jan, 2022: Emergency Use Authorization given by US
22 Dec, 2021: Complete Approval given by UK
11 Dec, 2021: Emergency Use Authorization given by Singapore
10 Dec, 2021: Complete Approval given by Switzerland
09 Dec, 2021: Emergency Use Authorization given by US
08 Dec, 2021: Emergency Use Authorization given by South Africa
07 Dec, 2021: Complete Approval given by Spain
05 Dec, 2021: Emergency Use Authorization given by Australia
02 Dec, 2021: Emergency Use Authorization given by Italy
28 Nov, 2021: Complete Approval given by Egypt
19 Nov, 2021: Complete Approval given by Canada
19 Nov, 2021: EUA Approval given by US
10 Nov, 2021: Complete Approval given by Japan
9 Nov, 2021: Complete Approval given by Canada
01 Nov, 2021: Emergency Use Authorization given by South Africa
29 Oct, 2021: Emergency Use Authorization given by US
27 Oct, 2021: Emergency Use Authorization given by Australia
8 Oct, 2021: Emergency Use Authorization given by Malaysia
22 Sep, 2021: Emergency Use Authorization given by US
16 Sep, 2021: Complete Approval given by Canada
23 Jun, 2021: Emergency Use Authorization given by Australia
15 Jul, 2021: Emergency Use Authorization given by Indonesia
24 Jun, 2021: Emergency Use Authorization given by Thailand
21 Jun, 2021: Complete Approval given by New-Zealand
15 Jun, 2021: Emergency Use Authorization given by Malaysia
15 Jun, 2021: Complete Approval given by US
12 Jun, 2021: Emergency Use Authorization given by Vietnam
11 Jun, 2021: Complete Approval given by Brazil
4 Jun, 2021: Emergency Use Authorization given by UK
2 Jun, 2021: Emergency Use Authorization given by Zambia
31 May, 2021: Emergency Use Authorization given by Pakistan
31 May, 2021: Emergency Use Authorization given by Italy
28 May,2021: Complete Approval given by EU
27 May, 2021: Emergency Use Authorization given by Bangladesh
13 May, 2021: Emergency Use Authorization given by United Arab Emirates
10 May, 2021: Emergency Use Authorization given by US
7 May, 2021: Emergency Use Authorization given by Sri Lanka
6 May, 2021: Emergency Use Authorization given by Canada
21 Mar, 2021: Emergency Use Authorization given by Libya
16 Mar, 2021: Emergency Use Authorization given by South Africa
15 Mar, 2021: Emergency Use Authorization given by Maldives
5 Mar, 2021: Emergency Use Authorization given by Republic of Korea
1 Mar,2021: Complete Approval given by Denmark
23 Feb,2021: Complete Approval given by Brazil
14 Feb,2021: Complete Approval given by Japan
10 Feb, 2021: Emergency Use Authorization given by New Zealand
2 Feb, 2021: Emergency Use Authorization given by Peru
25 Jan, 2021: Complete Approval given by Australia
25 Jan, 2021: Emergency Use Authorization given by Hong Kong
13 Jan, 2021: Emergency Use Authorization given by Philippines
11 Jan, 2021: Emergency Use Authorization given by Mongolia
6 Jan, 2021: Emergency Use Authorization given by Colombia
27 Dec, 2020: Emergency Use Authorization given by Iraq
25 Dec, 2020: Emergency Use Authorization given by Ireland
23 Dec, 2020: Emergency Use Authorization given by Argentina
21 Dec, 2020: Complete Approval given by EU
21 Dec, 2020: Emergency Use Authorization given by Qatar
19 Dec, 2020: Complete Approval given by Switzerland
17 Dec, 2020: Emergency Use Authorization given by Ecuador
16 Dec, 2020: Emergency Use Authorization given by Panama
16 Dec, 2020: Emergency Use Authorization given by Chile
16 Dec, 2020: Emergency Use Authorization given by Costa Rica
15 Dec, 2020: Emergency Use Authorization given by Oman
15 Dec, 2020: Emergency Use Authorization given by Jordan
14 Dec, 2020: Emergency Use Authorization given by Singapore
13 Dec, 2020: Emergency Use Authorization given by Kuwait
12 Dec, 2020: Emergency Use Authorization given by Mexico
11 Dec, 2020: Emergency Use Authorization given by US
10 Dec, 2020: Emergency Use Authorization given by Saudia Arabia
9 Dec, 2020: Emergency Use Authorization given by Canada
4 Dec, 2020: Emergency Use Authorization given by Bahrain
2 Dec, 2020: Emergency Use Authorization given by UK
Today

Moderna 30,420 2 8°C to -20°C 94.5% 30

Like Pfizer/BioNTech’s offering, is an mRNA vaccine with a nearly identical 95% efficacy for prevention of COVID-19. Also requires freezing temperatures but does not require ultra-low temperatures as Pfizer/BioNTech’s vaccine does.

Trial Start Date - 27 July 2020
Result Publication Date - 16 November 2020
12 Dec, 2022: Provisional Approval given by Japan
20 Oct, 2022: Emergency Use Authorization given by EU
20 Oct, 2022: Emergency Use Authorization given by Australia
24 Aug, 2022: Emergency Use Authorization given by Singapore
25 Jul, 2022: Conditional Marketing Authorization given by EU
18 Jul, 2022: Emergency Use Authorization given by Australia
14 Jul, 2022: Emergency Use Authorization given by the Canada
17 Jun, 2022: Emergency Use Authorization given by the US
31 May, 2022: Emergency Use Authorization given by the Philippines
13 May, 2022: Emergency Use Authorization given by the Switzerland
17 Apr, 2022: Emergency Use Authorization given by the Taiwan
14 Apr, 2022: Emergency Use Authorization given by the UK
29 Mar, 2022: Emergency Use Authorization given by the US
17 Mar, 2022: Complete Approval given by Canada
03 Mar, 2022: Complete Approval given by EU
16 Feb, 2022: Emergency Use Authorization given by Australia
08 Feb, 2022: Emergency Use Authorization given by Colombia
2 Feb, 2022: Complete Approval given by the US
16 Dec, 2021: Complete Approval given by Japan
8 Dec, 2021: Emergency Use Authorization given by Australia
19 Nov, 2021: Emergency Use Authorization given by US
12 Nov, 2021: Complete Approval given by Canada
20 Oct, 2021: Emergency Use Authorization given by the US
5 Oct, 2021: Emergency Use Authorization given by EU
16 Sep, 2021: Complete Approval given by Canada
5 Sep, 2021: Emergency Use Authorization given by Australia
4 Sep, 2021: Emergency Use Authorization given by Philippines
19 Aug, 2021: Emergency Use Authorization given by Mexico
13 Aug, 2021: Emergency Use Authorization given by US
9 Aug, 2021: Emergency Use Authorization given by Australia
5 Aug, 2021: Emergency Use Authorization given by Malaysia
30 Jul, 2021: Emergency Use Authorization given by Lithuania
2 Jul, 2021: Emergency Use Authorization given by Italy
26 Jul, 2021: Emergency Use Authorization given by Bhutan
9 Jul, 2021: Emergency Use Authorization given by Saudia Arabia
4 Jul, 2021: Emergency Use Authorization given by United Arab Emirates
2 Jul, 2021: Emergency Use Authorization given by Indonesia
30 Jun, 2021: Emergency Use Authorization given by India
30 Jun, 2021: Emergency Use Authorization given by Bangladesh
29 Jun, 2021: Emergency Use Authorization given by Vietnam
8 Jun, 2021: Emergency Use Authorization given by Maldives
21 May, 2021: Complete Approval given by South Korea
21 May, 2021: Emergency Use Authorization given by Japan
13 May, 2021: Emergency Use Authorization given by Thailand
6 May, 2021: Emergency Use Authorization given by Taiwan
13 May, 2021: Emergency Use Authorization given by Philippines
30 Apr, 2021: Emergency Use Listing (EUL) given by WHO
21 Mar, 2021: Emergency Use Authorization given by Libya
9 Feb, 2021: Emergency Use Authorization given by Qatar
3 Feb, 2021: Emergency Use Authorization given by Singapore
12 Jan, 2021: Emergency Use Authorization given by Switzerland
11 Jan, 2021: Emergency Use Authorization given by Mongolia
8 Jan, 2021: Emergency Use Authorization given by UK
8 Jan, 2021: Emergency Use Authorization given by France
6 Jan, 2021: Complete Approval given by EU
4 Jan, 2021: Authorization to import given by Israel
23 Dec, 2020: Emergency Use Authorization given by Canada
18 Dec, 2020: Emergency Use Authorization given by US
Today

AstraZeneca Plc 24,820 2 2 - 8°C 70.4% 53

Adenoviral vaccine which has produced mixed results depending on region, vaccine dosing regimen, schedule and SARS-CoV-2 variant. While overall efficacy may be lower than some competitors, protections against hospitalization and death is strong.

Trial Start Date - 28 May 2020
Result Publication Date - 08 December 2020
1 Nov, 2022: Complete Approval given by EU
23 May, 2022: Complete Approval given by EU
01 Feb, 2022: Emergency Use Authorization given by Thailand
27 Jan, 2022: Emergency Use Authorization given by India
15 Jan, 2022: Complete Approval given by Oman
17 Nov, 2021: Emergency Use Authorization given by Malaysia
14 Nov, 2021: Emergency Use Authorization given by Bahrain
28 Jul, 2021: Emergency Use Authorization given by New Zealand
2 Jun, 2021: Emergency Use Authorization given by Zambia
21 May, 2021: Emergency Use Authorization given by Japan
21 Mar, 2021: Emergency Use Authorization given by Libya
25 Mar, 2021: Emergency Use Authorization given by Finland
25 Mar, 2021: Emergency Use Authorization given by Iceland
18 Mar, 2021: Emergency Use Authorization given by Portugal
10 Mar, 2021: Emergency Use Authorization given by Papua New Guinea
10 Mar, 2021: Emergency Use Authorization given by Portugal
8 Mar, 2021: Emergency Use Authorization given by Indonesia
2 Mar, 2021: Emergency Use Authorization given by Malaysia
26 Feb, 2021: Emergency Use Authorization given by Canada
26 Feb, 2021: Emergency Use Authorization given by Costa Rica
24 Feb, 2021: Emergency Use Authorization given by Colombia
22 Feb, 2021: Emergency Use Authorization given by Ukraine
18 Feb, 2021: Emergency Use Authorization given by Saudi Arabia
18 Feb, 2021: Emergency Use Authorization given by Nigeria
17 Feb, 2021: Emergency Use Authorization given by Iran
16 Feb, 2021: Emergency Use Authorization given by Australia
15 Feb, 2021: Emergency Use Listing (EUL) given by WHO
12 Feb, 2021: Emergency Use Authorization given by Cambodia
10 Feb, 2021: Emergency Use Authorization given by South Korea
6 Feb, 2021: Complete Approval given by Spain
5 Feb, 2021: Emergency Use Authorization given by Greece
2 Feb, 2021: Complete Approval given by France
2 Feb, 2021: Complete Approval given by Sweden
1 Feb, 2021: Emergency Use Authorization given by Vietnam
1 Feb, 2021: Emergency Use Authorization given by Egypt
31 Jan, 2021: Emergency Use Authorization given by Kuwait
30 Jan, 2021: Complete Approval given by Italy
29 Jan, 2021: Complete Approval given by EU
29 Jan, 2021: Emergency Use Authorization given by Philippines
27 Jan, 2021: Emergency Use Authorization given by Chile
24 Jan, 2021: Emergency Use Authorization given by Ecuador
23 Jan, 2021: Emergency Use Authorization given by South Africa
23 Jan, 2021: Emergency Use Authorization given by Bhutan
22 Jan, 2021: Emergency Use Authorization given by Sri Lanka
21 Jan, 2021: Emergency Use Authorization given by Thailand
21 Jan, 2021: Emergency Use Authorization given by Hungary
19 Jan, 2021: Emergency Use Authorization given by Iraq
18 Jan, 2021: Emergency Use Authorization given by Brazil
17 Jan, 2021: Emergency Use Authorization given by Pakistan
15 Jan, 2021: Emergency Use Authorization given by Nepal
11 Jan, 2021: Emergency Use Authorization given by Mongolia
8 Jan, 2021: Emergency Use Authorization given by Bangladesh
6 Jan, 2021: Emergency Use Authorization given by India
6 Jan, 2021: Emergency Use Authorization given by Argentina
6 Jan, 2021: Emergency Use Authorization given by Dominican Republic
6 Jan, 2021: Emergency Use Authorization given by El Salvador
6 Jan, 2021: Emergency Use Authorization given by Mexico
6 Jan, 2021: Emergency Use Authorization given by Morocco
30 Dec, 2020: Emergency Use Authorization given by UK
Today

Novavax Inc 15,203 2 2 - 8°C 90.4% 18

Uses virus-like particles (VLPs) produced in insect cells and demonstrated 100% efficacy against variants "not considered Variants of Concern/Interest" and 93% efficacy against predominantly circulating Variants of Concern and Variants of Interest.

Trial Start Date - 28 September 2020
Result Publication Date - 11 March 2021
19 Jan, 2023: Expanded Authorization given by the South Korea
16 Jan, 2023: Emergency Use Authorization given by the India
22 Dec, 2022: Emergency Use Authorization given by the India
8 Dec, 2022: Complete Approval given by Canada
29 Nov, 2022: Emergency Use Listing given by WHO
29 Nov, 2022: Emergency Use Listing given by WHO
18 Nov, 2022: Expanded Authorization given by the Canada
9 Nov, 2022: Emergency Use Authorization given by the UK
19 Oct, 2022: Emergency Use Authorization given by the US
16 Sep, 2022: Expanded Emergency Use Authorization given by Taiwan
16 Sep, 2022: Emergency Use Authorization given by Israel
13 Sep, 2022: Complete Approval given by South Africa
12 Sep, 2022: Conditional Marketing Authorization given by EU
19 Aug, 2022: Emergency Use Authorization given by the Switzerland
5 Jul, 2022: Conditional Marketing Authorization given by UK
19 Aug, 2022: Emergency Use Authorization given by the US
18 Aug, 2022: Emergency Use Authorization given by New Zealand
17 Aug, 2022: Emergency Use Authorization given by New Zealand
12 Aug, 2022: Emergency Use Authorization given by South Korea
26 Jul, 2022: Emergency Use Authorization given by Australia
13 Jul, 2022: Emergency Use Authorization given by the US
5 Jul, 2022: Conditional Marketing Authorization given by EU
23 Jun, 2022: Emergency Use Authorization given by Taiwan
19 Apr, 2022: Complete Approval given by Japan
"13 Apr, 2022: Emergency Use Authorization given by Switzerland
" "08 Apr, 2022: Emergency Use Authorization given by Thailand
" "22 Mar, 2022: Emergency Use Authorization given by India
" "10 Mar, 2022: Restricted Emergency Use Authorization given by India
" "17 Feb, 2022: Emergency Use Authorization given by Canada
" "14 Feb, 2022: Emergency Use Authorization given by Singapore
" "03 Feb, 2022: Emergency Use Authorization given by New Zealand
" "03 Feb, 2022: Complete Approval given by UK
" "19 Jan, 2022: Emergency Use Authorization given by Australia
" "13 Jan, 2022: Complete Approval given by South Korea
" "28 Jun, 2022: Restricted Emergency Use Authorization given by India
" "24 Dec, 2021: Emergency Use Authorization given by Netherlands
" "20 Dec, 2021: Emergency Use Authorization given by EU
" "17 Dec, 2021: Emergency Use Listing given by WHO
" "18 Nov, 2021: Emergency Use Authorization given by Philippine
" 1 Nov, 2021: Emergency Use Authorization given by Indonesia
Today

Johnson & Johnson 44,325 1 2 - 8°C 66.0% 30

Adenoviral vaccine able to confer nearly 70% protection against all COVID-19 with a single dose. Like AstraZeneca’s vaccine, overall protection is not the highest, but offers near-complete protection against hospitalization and death. Also being tested as a two-dose regimen..

Trial Start Date - 07 September 2020
Result Publication Date - 29 January 2021
13 Mar, 2023: Emergency Use Authorization given by the US
09 Jan, 2023: Complete Approval given by EU
20 Jun, 2022: Complete Approval given by Japan
27 Feb, 2022: Emergency Use Listing (EUL) given by WHO
27 Feb, 2022: Emergency Use Authorization given by the US
24 Nov, 2021: Complete Approval given by Canada
21 Oct, 2021: Emergency Use Authorization given by the US
16 Sep, 2021: Emergency Use Authorization given by Iran
07 Sep, 2021: Emergency Use Authorization given by Indonesia
07 Aug, 2021: Emergency Use Authorization given by India
28 Jul, 2021: Emergency Use Authorization given by Zimbabwe
15 Jul, 2021: Emergency Use Authorization given by Vietnam
7 Jul, 2021: Provisional approval given by New Zealand
5 Jul, 2021: Emergency Use Authorization given by Ukraine
25 Jun, 2021: Provisional approval given by Australia
15 Jun, 2021: Emergency Use Authorization given by Malaysia
15 Jun, 2021: Emergency Use Authorization given by Bangladesh
11 Jun, 2021: Emergency Use Authorization given by Chile
8 Jun, 2021: Emergency Use Authorization given by Kuwait
8 Jun, 2021: Emergency Use Authorization given by Maldives
2 Jun, 2021: Emergency Use Authorization given by Zambia
28 May, 2021: Conditional Marketing Authorization given by UK
28 May, 2021: Emergency Use Authorization given by Mexico
20 Apr, 2021: Emergency Use Authorization given by Philippines
8 Apr, 2021: Emergency Use Authorization given by Tunisia
07 Apr, 2021: Conditional Marketing Authorization given by South Korea
1 Apr, 2021: Emergency Use Authorization given by Brazil
21 Mar, 2021: Emergency Use Authorization given by Libya
26 Mar, 2021: Emergency Use Authorization given by Colombia
25 Mar, 2021: Emergency Use Authorization given by Thiland
26 Mar, 2021: Emergency Use Authorization given by Switzerland
12 Mar, 2021: Conditional Marketing Authorization given by Italy
12 Mar, 2021: Conditional Marketing Authorization given by France
12 Mar, 2021: Emergency Use Listing (EUL) given by WHO
11 Mar, 2021: Conditional Marketing Authorization given by EU
5 Mar, 2021: Emergency Use Authorization given by Canada
27 Feb, 2021: Emergency Use Authorization given by the US
25 Feb, 2021: Emergency Use Authorization given by the US
https://www.aljazeera.com/news/2021/2/17/south-africa-begins-vaccine-rollout-through-observational-study
Today

Sinovac Biotech 29,608 2 2 - 8°C 50.7% 28

Vaccine from China, one of few vaccines using inactivated SARS-CoV-2 viruses which is a much more conventional vaccine technology than others which have demonstrated positive Phase III data.

Early Approval - 11 January 2021
Trial Start Date - 21 July 2020
Result Publication Date - 03 February 2021
3 Feb, 2023: Emergency Use Authorization given by Turkey
20 Dec, 2022: Complete Approval given by Hong Kong
9 Dec, 2022: Emergency Use Authorization given by Germany
23 Nov, 2022: Emergency use listing (EUL) given by WHO
18 Oct, 2022: Emergency Use Authorization given by Philippines
3 Aug, 2022: Emergency Use Authorization given by Hong Kong
13 Jul, 2022: Emergency Use Authorization given by Brazil
25 Jun, 2022: Emergency Use Authorization given by South Africa
14 Mar, 2022: Emergency Use Authorization given by Philippine
04 Mar, 2022: Emergency Use Authorization given by Malaysia
05 Feb, 2022: Emergency Use Authorization given by Thailand
01 Feb, 2022: Emergency Use Authorization given by Thailand
20 Jan, 2022: Emergency Use Authorization given by Brazil
20 Nov, 2021: Emergency Use Authorization given by Hong Kong
17 Nov, 2021: Emergency Use Authorization given by Malaysia
12 Nov, 2021: Emergency Use Authorization given by Pakistan
1 Oct, 2021: Emergency Use Authorization given by Malaysia
9 Sep, 2021: Emergency Use Authorization given by Chile
25 Aug, 2021: Emergency Use Authorization given by Saudi Arabia
17 Jul, 2021: Emergency Use Authorization given by Sri Lanka
3 Jul, 2021: Emergency Use Authorization given by South Africa
24 Jun, 2021: Emergency Use Authorization given by Oman
11 Jun, 2021: Emergency Use Authorization given by China
6 Jun, 2021: Emergency Use Authorization given by Bangladesh
4 Jun, 2021: Emergency Use Authorization given by Nepal
2 Jun, 2021: Emergency use listing (EUL) given by WHO
27 Apr, 2021: Emergency Use Authorization given by Egypt
10 Apr, 2021: Emergency Use Authorization given by Pakistan
9 Apr, 2021: Emergency Use Authorization given by Panama
10 Mar, 2021: Complete Approval given by Ukraine
10 Mar, 2021: Emergency Use Authorization given by Zimbabwe
05 Mar, 2021: Complete Approval given by Tunisia
" 2 Mar, 2021: Emergency Use Authorization given by Malaysia
26 Feb, 2021: Emergency Use Authorization given by Hong Kong
26 Feb, 2021: Emergency Use Authorization given by Ecuador
22 Feb, 2021: Emergency Use Authorization given by Philippines
22 Feb, 2021: Emergency Use Authorization given by Thailand
13 Feb, 2021: Emergency Use Authorization given by Cambodia
11 Feb, 2021: Emergency Use Authorization given by Mexico
8 Feb, 2021: Emergency Use Authorization given by China
6 Feb, 2021: Emergency Use Authorization given by Lao People's Democratic Republic
6 Feb, 2021: Emergency Use Authorization given by Uruguay
5 Feb, 2021: Emergency Use Authorization given by Colombia
21 Jan, 2021: Emergency Use Authorization given by Chile
18 Jan, 2021: Emergency Use Authorization given by Brazil
13 Jan, 2021: Emergency Use Authorization given by Turkey
11 Jan, 2021: Emergency Use Authorization given by Indonesia
Today

Gamaleya - Sputnik V 33,758 2 2 - 8°C 91.4% 74

Developed by Russia, uses two different adenoviruses, one for each of two doses, as part of a heterologous vaccination plan. Has shown excellent efficacy of just over 90% in preventing all COVID-19.

Early Approval - 12 August 2020
Trial Start Date - 07 September 2020
Result Publication Date - 14 December 2020
02 Apr, 2022: Complete Approval given by Russia
04 Feb, 2022: Complete Approval given by Russia
31 Oct, 2021: Emergency Use Authorization given by Cambodia
25 Aug, 2021: Emergency Use Authorization given by Indonesia
21 Jul, 2021: Emergency Use Authorization given by Chile
15 Jul, 2021: Emergency Use Authorization given by Nigeria
24 Jun, 2021: Emergency Use Authorization given by Oman
5 Jun, 2020: Conditional Approval given by Brazil
15 May, 2021: Emergency Use Authorization given by Republic of Ecuador
13 May, 2021: Emergency Use Authorization given by Maldives
30 Apr, 2021: Emergency Use Authorization given by Turkey
30 Apr, 2021: Emergency Use Authorization given by Albania
27 Apr, 2021: Emergency Use Authorization given by Bangladesh
20 Apr, 2021: Emergency Use Authorization given by Nepal
12 Apr, 2021: Emergency Use Authorization given by India
1 Apr, 2021: Emergency Use Authorization given by Panama
30 Mar, 2021: Emergency Use Authorization given by Mali
26 Mar, 2021: Emergency Use Authorization given by Antigua
26 Mar, 2021: Emergency Use Authorization given by Barbuda
23 Mar, 2021: Emergency Use Authorization given by Vietnam
22 Mar, 2021: Emergency Use Authorization given by Mauritius
19 Mar, 2021: Emergency Use Authorization given by Cameroon
19 Mar, 2021: Emergency Use Authorization given by Philippines
19 Mar, 2021: Emergency Use Authorization given by Republic of Seychelles
12 Mar, 2021: Emergency Use Authorization given by Azerbaijan
11 Mar, 2021: Emergency Use Authorization given by Namibia
10 Mar, 2021: Emergency Use Authorization given by Jordan
10 Mar, 2021: Emergency Use Authorization given by Kenya
10 Mar, 2021: Emergency Use Authorization given by Morocco
9 Mar, 2021: Emergency Use Authorization given by Zimbabwe
7 Mar, 2021: Emergency Use Authorization given by Macedonia
7 Mar, 2021: Emergency Use Authorization given by North Macedonia
4 Mar, 2021: Emergency Use Authorization given by Sri Lanka
4 Mar, 2021: Emergency Use Authorization given by Iraq
4 Mar, 2021: Emergency Use Authorization given by Laos
3 Mar, 2021: Emergency Use Authorization given by Angola
3 Mar, 2021: Emergency Use Authorization given by Djibouti
3 Mar, 2021: Emergency Use Authorization given by Republic of the Congo
1 Mar, 2021: Emergency Use Authorization given by Slovakia
26 Feb, 2021: Emergency Use Authorization given by Republic of Moldova
25 Feb, 2021: Emergency Use Authorization given by Guatemala
24 Feb, 2021: Emergency Use Authorization given by Egypt
24 Feb, 2021: Emergency Use Authorization given by Honduras
23 Feb, 2021: Emergency Use Authorization given by Kyrgyzstan
23 Feb, 2021: Emergency Use Authorization given by Guyana
20 Feb, 2021: Emergency Use Authorization given by Ghana
19 Feb, 2021: Emergency Use Authorization given by San Marino
17 Feb, 2021: Emergency Use Authorization given by Gabon
17 Feb, 2021: Emergency Use Authorization given by Uzbekistan
12 Feb, 2021: Emergency Use Authorization given by Montenegro
12 Feb, 2021: Emergency Use Authorization given by Saint Vincent and the Grenadines
10 Feb, 2021: Emergency Use Authorization given by Bahrain
9 Feb, 2021: Emergency Use Authorization given by Mongolia
9 Feb, 2021: Emergency Use Authorization given by Pakistan
9 Feb, 2021: Emergency Use Authorization given by Mongolia
6 Feb, 2021: Emergency Use Authorization given by Myanmar
6 Feb, 2021: Emergency Use Authorization given by Bosnia and Herzegovina
5 Feb, 2021: Emergency Use Authorization given by Lebanon
3 Feb, 2021: Emergency Use Authorization given by Mexico
3 Feb, 2021: Emergency Use Authorization given by Nicaragua
3 Feb, 2021: Emergency Use Authorization given by Nicaragua
1 Feb, 2021: Emergency Use Authorization given by Armenia
30 Jan, 2021: Emergency Use Authorization given by Tunisia
29 Jan, 2021: Emergency Use Authorization given by Republic of Guinea
26 Jan, 2021: Emergency Use Authorization given by Iran
21 Jan, 2021: Emergency Use Authorization given by Hungary
21 Jan, 2021: Emergency Use Authorization given by UAE
18 Jan, 2021: Emergency Use Authorization given by Turkmenistan
15 Jan, 2021: Emergency Use Authorization given by Paraguay
14 Jan, 2021: Temporary Registration given by Kazakhstan
13 Jan, 2021: Emergency Use Authorization given by Venezuela
11 Jan, 2021: Emergency Use Authorization given by Palestine
10 Jan, 2021: Emergency Use Authorization given by Algeria
6 Jan, 2021: Emergency Use Authorization given by Bolivia
31 Dec, 2020: Emergency Use Authorization given by Serbia
28 Dec, 2020: Approved by Russia for population aged 60 years and above
23 Dec, 2020: Emergency Use Authorization given by Argentina
21 Dec, 2020: Emergency Use Authorization given by Belarus
12 Aug, 2020: EUA given by Russia
Today

CanSino Biologics 40,000 1 2 - 8°C 65.7% 10

Like Johnson & Johnson’s vaccine, this vaccine from China showed just under 70% efficacy in preventing all COVID-19 and 90% efficacy in preventing severe COVID-19 with just a single dose.

Early Approval - 25 June 2020
Trial Start Date - 15 September 2020
Result Publication Date - 01 March 2023
01 Mar, 2023: Emergency Use Authorization given by Indonesia
10 Nov, 2022: Emergency Use Authorization given by Morocco
4 Sep, 2022: Emergency Use Authorization given by China
1 Jul, 2022: Emergency Use Authorization given by Malaysia
19 May, 2022: Emergency Use Listing given by WHO
22 Mar, 2022: Emergency Use Authorization given by Indonesia
22 Mar, 2022: Emergency Use Authorization given by Malaysia
19 Feb, 2022: Complete approval given by China
07 Sep, 2021: Emergency Use Authorization given by Indonesia
16 Jun, 2021: Complete approval given by Ecuador
15 Jun, 2021: Emergency Use Authorization given by Malaysia
12 Jun, 2021: Emergency Use Authorization given by Argentina
8 Apr, 2021: Emergency Use Authorization given by Chile
22 Mar, 2021: Emergency Use Authorization given by Hungary
12 Feb, 2021: Emergency Use Authorization given by Pakistan
11 Feb, 2021: Emergency Use Authorization given by Mexico
25 Jun, 2020: Military Use Authorization given by China
Today

Sinopharm 60,000 2 2 - 8°C 86.0% 36

The second inactivated vaccine, also being developed by China, has shown mixed results in Brazil, where initial efficacy was 86% based on data from the UAE, but efficacy data from Brazil were significantly lower at only 50%.

Early Approval - 10 December 2020
Trial Start Date - 16 July 2020
Result Publication Date - 31 December 2020
9 May, 2022: Complete Approval given by Myanamar
22 Mar, 2022: Emergency Use Authorization given by Indonesia
07 Feb, 2022: Emergency Use Authorization given by South Africa
05 Feb, 2022: Emergency Use Authorization given by Thailand
28 Dec, 2021: Emergency Use Authorization given by UAE
12 Nov, 2021: Emergency Use Authorization given by Pakistan
2 Oct, 2021: Emergency Use Authorization given by Argentina
21 Aug, 2021: Emergency Use Authorization given by Mexico
25 Aug, 2021: Emergency Use Authorization given by Saudi Arabia
24 Aug, 2021: Emergency Use Authorization given by Nigeria
19 Aug, 2021: Emergency Use Authorization given by Kenya
16 Jul, 2021: Emergency Use Authorization given by Malaysia
12 Jul, 2021: Emergency Use Authorization given by Tunisia
9 Jul, 2021: Emergency Use Authorization given by Trinidad and Tobago
18 Jun, 2021: Emergency Use Authorization given by Gambia
11 Jun, 2021: Emergency Use Authorization given by China
7 Jun, 2021: Emergency Use Authorization given by Philippines
4 June, 2021: Emergency Use Authorization given by Vietnam
2 Jun, 2021: Emergency Use Authorization given by Zambia
29 May, 2021: Emergency Use Authorization given by Bangladesh
28 May, 2021: Emergency Use Authorization given by Thailand
07 May, 2021: Emergency Use Authorization given by WHO
29 Apr, 2021: Emergency Use Authorization given by Indonesia
20 Mar, 2021: Emergency Use Authorization given by Sri Lanka
16 Mar, 2021: Emergency Use Authorization given by Maldives
11 Mar, 2021: Emergency Use Authorization given by Iran
9 Mar, 2021: Emergency Use Authorization given by Zimbabwe
1 Mar, 2021: Emergency Use Authorization given by Venezuela
26 Feb, 2021: Emergency Use Authorization given by Guyana
22 Feb, 2021: Emergency Use Authorization given by Argentina
18-Feb, 2021: Emergency Use Authorization given by Nepal
4 Feb, 2021: Emergency Use Authorization given by Cambodia
29 Jan, 2021: Emergency Use Authorization given by Hungary
27 Jan, 2021: Emergency Use Authorization given by Peru
24 Jan, 2021: Emergency Use Authorization given by Morocco
19 Jan, 2021: Emergency Use Authorization given by Pakistan
19 Jan, 2021: Emergency Use Authorization given by Iraq
18 Jan, 2021: Emergency Use Authorization given by Republic of Serbia
9 Jan, 2021: Emergency Use Authorization given by Jordan
4 Jan, 2021: Emergency Use Authorization given by Egypt
2 Jan, 2021: Emergency Use Authorization given by China
14 Dec, 2020: Emergency Use Authorization given by Bahrain
10 Dec, 2020: Complete Approval given by UAE
Today

Bharat Biotech 25,800 2 2 - 8°C 81.0% 13

Adjuvanted inactivated vaccine produced in Vero cells and developed by India, showed 81% efficacy in preventing COVID-19 after two doses.

Early Approval - 03 January 2021
Trial Start Date - 16 November 2020
Result Publication Date - 01 March 2021
26 Apr, 2022: Emergency Use Authorization given by India
11 Feb, 2022: Emergency Use Authorization given by Malaysia
27 Jan, 2022: Emergency Use Authorization given by India
27 Dec, 2021: Emergency Use Authorization given by India
12 Nov, 2021: Emergency Use Authorization given by Bahrain
10 Nov, 2021: Emergency Use Authorization given by Hong Kong
10 Nov, 2021: Emergency Use Authorization given by Hong Kong
8 Nov, 2021: Emergency Use Authorization given by Trinidad and Tobago
3 Nov, 2021: Emergency Use Authorization given by WHO
2 Nov, 2021: Emergency Use Authorization given by Guyana
20 Apr, 2021: Emergency Use Authorization given by Philippines
6 Apr, 2021: Emergency Use Authorization given by Mexico
26 Mar, 2021: Complete Approval given by Mauritius
21 Mar, 2021: Emergency Use Authorization given by Nepal
04 Mar, 2021: Emergency Use Authorization given by Zimbabwe
19 Feb, 2021: Emergency Use Authorization given by Iran
3 Jan, 2021: Restricted Emergency Use Authorization given by India
Today

Gamaleya - Sputnik Light 110 1 2 - 8°C 79.4% 23

Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V, showed 79.4% efficacy from 28 days after the injection was administered as part of Russia’s mass vaccination program.

Early Approval - 06 May 2021
Trial Start Date - 15 January 2021
Result Publication Date - 06 May 2021
7 Feb, 2022: Restricted Emergency Use Authorization given by India
29 Dec, 2021: Complete Approval given by Tunisia
6 Dec, 2021: Emergency Use Authorization given by Argentina
30 Nov, 2021: Emergency Use Authorization given by UAE
23 Nov, 2021: Emergency Use Authorization given by Laos
23 Nov, 2021: Emergency Use Authorization given by San Marino
31 Oct, 2021: Emergency Use Authorization given by Cambodia
6 Oct, 2021: Emergency Use Authorization given by UAE
24 Sep, 2021: Emergency Use Authorization given by Egypt
16 Sep, 2021: Emergency Use Authorization given by Iran
06 Sep, 2021: Complete Approval given by Armenia
23 Aug, 2021: Emergency Use Authorization given by Philippines
15 Jul, 2021: Complete Approval given by Kazakhstan
25 Jun, 2021: Emergency Use Authorization given by Kyrgyzstan
11 Jun, 2021: Emergency Use Authorization given by Mongolia
7 Jun, 2021: Emergency Use Authorization given by Republic of the Congo
3 Jun, 2021: Emergency Use Authorization given by Belarus
2 Jun, 2021: Emergency Use Authorization given by Mauritius
31 May, 2021: Emergency Use Authorization given by Palestine
21 May, 2021: Emergency Use Authorization given by Nicaragua
15 May, 2021: Emergency Use Authorization given by Venezuela
12 May, 2021: Emergency Use Authorization given by Angola
11 May, 2021: Emergency Use Authorization given by Bahrain
6 May, 2021: Complete Approval given by Russia
Today

Cadila Healthcare Ltd - ZyCoV-D 28,000 2 2 - 8°C 66.6% 1

ZyCoV-D is the first plasmid DNA, needle-free vaccine against COVID-19, showing 66.6% efficacy after the third injection was administered in over 28,000 volunteers at more than 50 clinical sites spread across India.

Early Approval - 20 August 2021
Trial Start Date - 20 January 2021
Result Publication Date - 01 July 2021
26 Apr, 2022: Emergency Use Authorization given by India
20 Aug, 2021: Emergency Use Authorization given by India
Today

Biological E Ltd - CORBEVAX 3,000 2 2 - 8°C 90.0% 2

CORBEVAX is a recombinant protein sub-unit vaccine, developed from the receptor binding domain (RBD) of the spike protein on the virus’s surface combined with Dynavax’s CpG 1018 adjuvant with alum. It Showed >90% efficacy against Wuhan strain and >80% efficacy against Delta Strain.

Early Approval - 28 December 2021
Trial Start Date - 01 January 1970
Result Publication Date - 01 January 1970
10 August, 2022: Emergency Use Authorization given by India
5 June, 2022: Emergency Use Authorization given by India
26 Apr, 2022: Emergency Use Authorization given by India
29 Mar, 2022: Complete Approval given by Botswana
28 Dec, 2021: Restricted Emergency Use Authorization given by India
28 Dec, 2021: Restricted Emergency Use Authorization given by India
Today

Medicago Inc - COVIFENZ 753 2 2 - 8°C 71% 1

COVIFENZ is composed of recombinant spike (S) glycoprotein expressed as virus-like particles (VLPs) using Coronavirus-Like Particle (CoVLP) technology and is co-administered with GSK’s pandemic adjuvant. The vaccination regimen calls for two doses given intramuscularly 21 days apart. The vaccine is stored at 2 °C to 8 °C.

Early Approval - 07 December 2021
Trial Start Date - 19 November 2020
Result Publication Date - 24 February 2022
24 Feb, 2022: Complete Approval given by Canada
Today

Valneva SE - VLA2001 4 2 2 - 8°C 95% 4

VLA2001 is produced on Valneva’s established Vero-cell platform, leveraging the manufacturing technology for Valneva’s licensed Japanese encephalitis vaccine, IXIARO. VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018.

Early Approval - 18 October 2021
Trial Start Date - 26 April 2021
Result Publication Date - 01 March 2022
19 Aug, 2022: Emergency Use Authorization given by WHO
24 Jun, 2022: Complete Approval given by EU
16 May, 2022: Emergency Use Authorization given by United Arab Emirates
14 Apr, 2022: Complete Approval given by UK
1 Mar, 2022: Emergency Use Authorization given by Bahrain
Today

Moderna Inc - Spikevax Bivalent Original/Omicron BA.1 4 1 8°C to -50°C 94.1% 8

Spikevax Bivalent Original/Omicron is a next-generation bivalent vaccine that contains mRNA-1273 (Spikevax) and a vaccine candidate targeting the Omicron variant of concern (BA.1). It is indicated as a booster dose for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

Early Approval - 08 June 2022
Trial Start Date - 28 May 2021
Result Publication Date - 12 August 2022
17 Feb, 2023: Emergency Use Authorization given by Canada
16 Dec, 2022: Emergency Use Authorization given by the EU
12 Dec, 2022: Provisional Approval given by Japan
16 Sep, 2022: Emergency Use Authorization given by the EU
12 Sep, 2022: Complete Approval given by Japan
1 Sep, 2022: Emergency Use Authorization given by Canada
30 Aug, 2022: Provisional approval given by Australia
29 Aug, 2022: Temporary Authorization given by Switzerland
12 Aug, 2022: Conditional Approval given by UK
Today

Pfizer/BioNTech - Comirnaty bivalent Original/Omicron (BA.1) 1 1 2 - 8°C 95% 8

Comirnaty bivalent Original/Omicron (BA.1) is a bivalent vaccine that contains Comirnaty and a vaccine candidate targeting the Omicron variant of concern (BA.1). It is indicated as a booster dose for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.

Early Approval - 03 September 2022
Trial Start Date - 25 January 2022
Result Publication Date - 22 November 2022
22 Nov, 2022: Emergency Use Authorization given by the Brazil
15 Nov, 2022: Provisional Approval given by the Australia
28 Oct, 2022: Provisional Approval given by the Australia
10 Oct, 2022: Temporary Authorization given by Switzerland
12 Sep, 2022: Emergency Use Authorization given by the EU
3 Sep, 2022: Conditional Approval given by UK
Today

Moderna Inc - Covid-19 mRNA [Omicron Ba.4/Ba.5] (Bivalent) Vaccine 5 1 2 - 8°C 10

BA.4/.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222 targets the BA.4/.5 subvariants of Omicron. 50 µg booster dose indicated for adults over 18 years of age who have received either a primary series or an initial booster of any of the authorized or approved COVID-19 vaccines. The 50 µg booster dose of mRNA-1273.222 includes 25 µg of mRNA encoding for the spike protein of BA.4/.5 and 25 µg encoding for the original strain of the SARS-CoV-2 virus.

Early Approval - 31 August 2022
Trial Start Date - 28 May 2021
Result Publication Date - 31 August 2022
17 Feb, 2022: Provisional Approval given by the Australia
12 Dec, 2022: Provisional Approval given by Japan
8 Dec, 2022: Emergency Use Authorization given by the US
2 Dec, 2022: Emergency Use Authorization given by South Korea
3 Nov, 2022: Emergency Use Authorization given by Canada
1 Nov, 2022: Emergency Use Authorization given by Japan
26 Oct, 2022: Emergency Use Authorization given by the Taiwan
23 Oct, 2022: Interim Authorization given by the Singapore
20 Oct, 2022: Emergency Use Authorization given by the EU
12 Oct, 2022: Emergency Use Authorization given by the US
31 Aug, 2022: Emergency Use Authorization given by the US
Today

Pfizer/BioNTech - Comirnaty Bivalent Original/Omicron BA.4/BA.5 1 2 - 8°C 14

Omicron BA.4/BA.5 Bivalent Vaccine combines 15-µg of mRNA encoding the wild-type spike protein found in the Original Pfizer-BioNTech COVID-19 Vaccine and 15-µg of mRNA encoding the spike protein of the OmicronBA.4/BA.5 subvariants. 30-µg booster dose of Bivalent (Original [15 µg] and Omicron BA.4/BA.5 [15 µg]) approved for individuals ages 12 years and older.

Early Approval - 01 January 1970
Trial Start Date - 31 August 2022
Result Publication Date - 20 January 2023
14 Mar, 2023: Emergency Use Authorization given by the US
20 Jan, 2023: Emergency Use Authorization given by the Macau
22 Nov, 2022: Emergency Use Authorization given by the Brazil
20 Jan, 2023: Provisional Approval given by Australia
27 Dec, 2022: Emergency Use Authorization given by the Nepal
23 Dec, 2022: Complete Approval given by Hong Kong
14 Dec, 2022: Conditional Approval given by Malaysia
9 Dec, 2022: Emergency Use Authorization given by the Canada
8 Dec, 2022: Emergency Use Authorization given by the US
18 Nov, 2022: Emergency Use Authorization given by the Hong Kong
10 Nov, 2022: Emergency Use Authorization given by the UK
10 Nov, 2022: Emergency Use Authorization given by the EU
26 Oct, 2022: Emergency Use Authorization given by the Taiwan
25 Oct, 2022: EInterim Authorization given by the Singapore
12 Oct, 2022: Emergency Use Authorization given by the US
7 Oct, 2022: Emergency Use Authorization given by Canada
5 Oct, 2022: Emergency Use Authorization given by Japan
16 Sep, 2022: Emergency Use Authorization given by the EU
31 Aug, 2022: Emergency Use Authorization given by the US
Today

Bharat Biotech Ltd - iNCOVACC 3 2 2 - 8°C 1

"iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a prefusion stabilized spike protein. It has been specifically formulated to allow intranasal delivery through nasal drops. iNCOVACC received approval under Restricted Use in Emergency Situation for ages 18 and above"

Early Approval - 15 August 2021
Trial Start Date - 31 August 2021
Result Publication Date - 06 September 2022
2 Dec, 2022: Restricted Emergency Use Authorization given by India
25 Nov, 2022: Restricted Emergency Use Authorization given by India
6 Sep, 2022: Restricted Emergency Use Authorization given by India
Today

Suzhou Abogen Biosciences Co Ltd - AWcorna 28,000 2 2 - 8°C 83.58% 1

The vaccine is presented in 0.5 mL prefilled syringe, with mRNA encoding the RBD of the spike glycoprotein (S protein) of SARS-CoV-2 as the active substance.

Early Approval - 30 September 2022
Trial Start Date - 22 July 2021
Result Publication Date - 30 September 2022
30 Sep, 2022: Emergency Use Authorization given by Indonesia
Today

PT Bio Farma - Indovac 900 2 2 - 8°C 1

The Indovac vaccine contains the recombinant Receptor-Binding Domain (RBD) protein S of the SARS-Cov-2 virus, is a COVID-19 vaccine with a recombinant protein subunit platform.

Early Approval - 01 January 1970
Trial Start Date - 01 September 2022
Result Publication Date - 30 September 2022
21 Apr, 2023: Emergency Use Authorization given by Indonesia
22 Nov, 2022: Emergency Use Authorization given by Indonesia
30 Sep, 2022: Emergency Use Authorization given by Indonesia
Today

PT Biotis Pharmaceutical Indonesia - Inavac 4 2 2 - 8°C 1

The Inavac vaccine is a COVID-19 vaccine with an inactivated virus platform developed by researchers at Airlangga University and produced and registered by PT Biotis Pharmaceuticals Indonesia (PT Biotis).

Early Approval - 04 November 2022
Trial Start Date - 28 June 2022
Result Publication Date - 01 November 2022
01 Nov, 2022: Emergency Use Authorization given by Indonesia
Today

Shenzhen Kangtai Biological Products Co Ltd - Kconvac 2 2 - 8°C 2

Coronavirus Disease  2019 (COVID-19) vaccine (Kconvac/ Kconecavac) is a inactivated vaccine composed of SARS-CoV-2 virus antigen

Early Approval - 01 January 1970
Trial Start Date - 01 January 1970
Result Publication Date - 15 May 2021
21 Feb, 2022: Emergency Use Authorization given by China
11 Jan, 2022: Emergency Use Authorization given by Indonesia
03 Nov, 2021: Emergency Use Authorization given by Indonesia
15 May, 2021: Emergency Use Authorization given by China
Today

SK Bioscience Ltd - SKYCovione 4 2 2 - 8°C 1

SKYCovione is a self-assembled nanoparticle vaccine targeting the receptor binding domain of the SARS-CoV-2 Spike protein for the parental SARS-Cov-2, jointly developed with the Institute for Protein Design (IPD) at the University of Washington School of Medicine with combination of GSK’s pandemic adjuvant.

Early Approval - 29 June 2022
Trial Start Date - 30 August 2021
Result Publication Date - 29 June 2022
29 Jun, 2022: Complete Approval given by South Korea
Today

Federal Research Center for Research and Development of Immunobiological Preparations - KoviVac 32 2 2 - 8°C 2

KoviVac is an inactivated whole-virion concentrated purified coronavirus vaccine

Early Approval - 01 January 1970
Trial Start Date - 07 July 2021
Result Publication Date - 20 February 2021
16 Dec, 2022: Emergency Use Authorization given by Belarus
20 Feb, 2021: Complete Approval given by Russia
Today

PT Bio Farma - Cov2Bio 1 2 2 - 8°C 65.30% 1

Cov2Bio is a inactivated vaccine composed of SARS-CoV-2 virus antigen

Early Approval - 11 January 2021
Trial Start Date - 01 January 1970
Result Publication Date - 11 January 2021
11 Jan, 2021: Emergency Use Authorization given by Indonesia
Today

Center for Genetic Engineering and Biotechnology - Abdala 48 3 2 - 8°C 4

Abdala is a vaccine targeting SARS-CoV-2 virus receptor binding domain recombinant protein

Early Approval - 01 January 1970
Trial Start Date - 22 March 2021
Result Publication Date - 11 June 2021
29 Dec, 2021: Emergency Use Authorization given by Mexico
27 Oct, 2021: Emergency Use Authorization given by Cuba
3 Oct, 2021: Emergency Use Authorization given by Nicaragua
18 Sep, 2021: Complete Approval given by Vietnam
9 Jul, 2021: Emergency Use Authorization given by Cuba
Today

HDT Bio Corp - Gemcovac 2 2 - 8°C 1

Gemcovac is an in-vitro transcribed self-amplifying mRNA encoding for the S-protein of SARS-CoV-2 vaccine

Early Approval - 11 January 2021
Trial Start Date - 01 January 1970
Result Publication Date - 28 June 2022
28 Jun, 2022: Emergency Use Authorization given by India
Today

The State Research Center of Virology and Biotechnology VECTOR - EpiVacCorona 100 2 2 - 8°C 3

EpiVacCorona is a synthetic peptide antigen based vaccine . It contains protein S of the SARS-CoV-2 virus, conjugated to the carrier protein

Early Approval - 01 January 1970
Trial Start Date - 27 July 2020
Result Publication Date - 13 October 2020
30 Oct, 2021: Emergency Use Authorization given by Cambodia
29 Jan, 2021: Complete Approval given by Turkmenistan
13 Oct, 2020: Complete Approval given by Russia
Today

Chongqing Zhifei Biological Products Co Ltd - Zifivax 50 2 2 - 8°C 6

 Zifivax is a recombinant protein subunit vaccine composed of new coronavirus spike glycoprotein receptor binding region NCP-RBD protein

Early Approval - 22 December 2020
Trial Start Date - 22 June 2020
Result Publication Date - 01 March 2021
5 Jan, 2023: Conditional Approval given by Belarus
22 Dec, 2022: Emergency Use Authorization given by Kenya
28 Jan, 2022: Emergency Use Authorization given by Colombia
7 Oct, 2021: Emergency Use Authorization given by Indonesia
10 Mar, 2021: Emergency Use Authorization given by China
1 Mar, 2021: Complete Approval given by Uzbekistan
Today

Livzon Pharmaceutical Group Co Ltd - V-01 10 2 2 - 8°C 61.35% 1

V-01 is a recombinant SARS-CoV-2 fusion protein vaccine

Early Approval - 16 February 2022
Trial Start Date - 03 November 2021
Result Publication Date - 02 September 2022
2 Sep, 2022: Emergency Use Authorization given by China
Today

Sanofi - Vidprevtyn 247 1 2 - 8°C 76.1%  2

Vidprevtyn is a recombinant baculovirus vaccine and comprises of recombinant S-protein COVID-19 antigen expressed in Baculo virus expression system

Early Approval - 13 June 2022
Trial Start Date - 08 December 2021
Result Publication Date - 10 November 2021
21 Dec, 2022: Emergency Use Authorization given by UK
10 Nov, 2022: Emergency Use Authorization given by EU
Today

Chinese Academy of Sciences - Covidful 2 2 - 8°C 99.33% 1

Covidful is an inactivated vaccine composed of inactivated SARS-CoV-2 virus antigen

Early Approval - 09 June 2021
Trial Start Date - 01 January 1970
Result Publication Date - 09 June 2021
9 Jun, 2021: Emergency Use Authorization given by China
Today

MC Pharma (Pty) Ltd - Sars-Cov-2 (Inactivated) Vaccine 2 2 - 8°C 79.00% 1

The vaccine is an inactivated whole virion vaccine composed of inactivated SARS-CoV-2 virus antigen

Early Approval - 10 July 2022
Trial Start Date - 01 January 1970
Result Publication Date - 16 September 2022
16 Sep, 2022: Emergency Use Authorization given by South Africa
Today

Sinopharm Group Co Ltd - Inactivated SARS-CoV-2 Vaccine (Vero cell) 45 2 2 - 8°C 79.34% 2

The vaccine is an inactivated vaccine composed of inactivated novel coronavirus antigen

Early Approval - 31 December 2020
Trial Start Date - 16 July 2020
Result Publication Date - 25 February 2021
19 Aug, 2021: Emergency Use Authorization given by Philippines
18 Aug, 2021: Emergency Use Authorization given by China
25 Feb, 2021: Emergency Use Authorization given by China
Today

University of Hong Kong - VectorFlu ONE 31 2 2 - 8°C 80.00% 1

 Intranasal Covid19 vaccine developed by researchers at the University of Hong Kong (HKU) in collaboration with Xiamen University and Wantai pharmaceutical. It comprises of influenza virus vector expressing receptor binding domain (RBD) of corona virus surface antigen. It is being developed by replicating viral vector platform

Early Approval - 05 December 2022
Trial Start Date - 16 December 2021
Result Publication Date - 06 December 2022
6 Dec, 2022: Emergency Use Authorization given by China
Today

SinoCelltech Group Ltd - SCTV01C 1 2 25 °C 1

SCTV01C is a new generation of bivalent mutant strain recombinant protein vaccine. The active ingredients of SCTV01C contain the recombinant S trimer protein antigens of the two major mutant strains identified by the WHO , Alpha ( Alpha ) and Beta ( Beta ), and adopt a new type of oil-in-water that can significantly enhance Th1 cells compared with traditional aluminum adjuvants

Early Approval - 04 December 2022
Trial Start Date - 10 May 2022
Result Publication Date - 06 December 2022
4 Dec, 2022: Emergency Use Authorization given by China
Today

WestVac Biopharma Co Ltd - Coviccine 2 2 - 8°C 1

The vaccine candidate comprises of recombinant proteins produced from the insect cells and target spike protein receptor-binding domain (S-RBD) of SARS-CoV-2.

Early Approval - 01 January 1970
Trial Start Date - 01 January 1970
Result Publication Date - 05 December 2022
5 Dec, 2022: Emergency Use Authorization given by China
Today

Stemirna Therapeutics Ltd - SWBIC-213 2 2 20(±5)°C 100.00% 1

SWBIC-213 is an mRNA vaccine developed for booster shot delivered with a lipopolyplex (LPP) nanoparticle.

Early Approval - 14 December 2022
Trial Start Date - 01 October 2022
Result Publication Date - 08 December 2022
8 Dec, 2022: Emergency Use Authorization given by Lao People's Democratic Republic
Today

Clover Biopharmaceuticals Ltd - SCB-2019 31 2 2 - 8°C 83.70% 1

SCB-2019 comprises of recombinant, trimeric spike (S) protein of Wuhan Coronavirus and is being developed based on trimer-tag technology.

Early Approval - 20 January 2022
Trial Start Date - 24 March 2021
Result Publication Date - 05 December 2022
5 Dec, 2022: Emergency Use Authorization given by China
Today

Finlay Vaccine Institute - Soberana 02 44 2 2 - 8°C 92.40% 4

Soberana 02 comprises conjugated recombinant receptor-binding domain (RBD) of SARS-CoV-2 and an adjuvant.

Early Approval - 06 November 2021
Trial Start Date - 08 March 2021
Result Publication Date - 29 June 2021
20 Nov, 2022: Emergency Use Authorization given by Mexico
3 Oct, 2021: Emergency Use Authorization given by Nicaragua
3 Sep, 2021: Emergency Use Authorization given by Cuba
20 Aug, 2021: Emergency Use Authorization given by Cuba
29 Jun, 2021: Emergency Use Authorization given by Iran
Today

Finlay Vaccine Institute - Soberana Plus 44 1 2 - 8°C 92.40% 3

Soberana Plus comprises of receptor-binding domain (RBD) of SARS-CoV-2 and an adjuvant.

Early Approval - 06 November 2021
Trial Start Date - 08 March 2021
Result Publication Date - 20 August 2021
20 Nov, 2022: Emergency Use Authorization given by Mexico
27 Jul, 2022: Emergency Use Authorization given by Belarus
3 Sep, 2021: Emergency Use Authorization given by Cuba
20 Aug, 2021: Emergency Use Authorization given by Cuba
Today

CSPC Pharmaceutical Group Ltd - SYS-6006 4,000 1 2 - 8°C 85.30% 1

SYS-6006 is a mRNA vaccine covering Omicron subvariant BA.5’s core mutation at the spike mutation positions.

Early Approval - 22 March 2023
Trial Start Date - 10 December 2022
Result Publication Date - 22 March 2023
22 Mar, 2023: Emergency Use Authorization given by China
Today

Jiangsu Recbio Technology Co Ltd - ReCOV 300 1 2 - 8°C 1

ReCOV is a recombinant COVID-19 vaccine being developed by Jiangsu Recbio with its technology platforms including the novel adjuvant and protein engineering platforms, and the adjuvant used therein is the self-developed novel adjuvant BFA03.

Early Approval - 20 March 2023
Trial Start Date - 30 May 2022
Result Publication Date - 20 March 2023
20 Mar, 2023: Emergency Use Authorization given by Mongolia
Today

Laboratorios Hipra SA - Bimervax 2 1 2 - 8°C 1

Bimervax is a bivalent adjuvanted vaccine containing a recombinant protein based on the Beta and Alpha variants of SARS-CoV-2.

Early Approval - 20 March 2023
Trial Start Date - 03 February 2022
Result Publication Date - 30 March 2023
30 Mar, 2023: Complete Approval given by EU
Today

Covid-19 vaccine clinical trials by region

Covid-19 vaccine clinical trials by trial phase

Covid-19 vaccine clinical trials by trial status

Covid-19 - The race to herd immunity

According to the World Health Organization (WHO), "Herd Immunity, also known as population immunity, is the indirect protection from an infectious disease that happens when a population is immune either through vaccination or immunity developed through previous infection."

Herd immunity against Covid-19 has been widely debated over the past months, however WHO has admitted, "we do not have a clear understanding of the herd immunity level for Covid-19."

So, what is the herd immunity percentage for Covid-19?

In the context of Covid-19, herd immunity level is 60-70%,but could be higher if the new variants of the virus are more contagious.

The assumption should always be higher rather than lower with some recent research suggesting the number of the population that needed to be vaccinated ranged from 69-93%.

Race to herd immunity (Top 20 countries by vaccination rate)

Race to herd immunity (Leading economies)